Ocular Therapeutix™ Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease
Go back to Ocular Therapeutix™ Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease| (NASDAQ: OCUL) | Delayed: 11.37 +0.73 (6.86%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.64 | 52 Week High | $14.50 | |||
| Open | $10.56 | 52 Week Low | $4.04 | |||
| Day High | $11.44 | P/E | N/A | |||
| Day Low | $10.40 | EPS | $0.00 | |||
| Volume | 2,737,329 | |||||
